A
Alcista
Alcista · 25%LLY
$1,138.36
Precio del escenario
$1,208.740
+43.756 (+3.62%)Al cierre
Loading chart…
- Máximo
- 1,216.714
- Apertura
- 1,177.870
- Precio medio ponderado por volumen
- 1,199.90
- Volumen
- 3.17M
- Capitalización
- 863.96B
- Mínimo
- 1,174.240
- Importe
- 3.80B
- EV/EBITDA, TTM
- 19.09
Eli Lilly and Company is a medicine company which discovers, develops, manufactures, and markets products in a single business segment called human pharmaceutical products. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. Its Cardiometabolic Health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients. The Company’s products are sold in approximately 90 countries.
Análisis de IA of Eli Lilly and Co (LLY)
ComprarEli Lilly is a good buy right now due to its current price of $1179.27, a strong year-to-date change of +9.16%, and a forward P/E ratio of 24.39, which suggests growth potential. The main risk is the high debt to equity ratio of 162.07%, indicating potential financial strain.
Recomendaciones de analistas (22)
Comprar
13 Comprar
8 Mantener
1 Vender
Actual: 1,208.74
Mínimo
950.00
Promedio
—
Máximo
—
BofA
Comprar
—
2026-10-09
BofA
2026-10-09
Precio objetivo
—
Comprar
Cantor Fitzgerald
Sobreponderar
—
2026-10-08
Cantor Fitzgerald
2026-10-08
Precio objetivo
—
Sobreponderar
Morgan Stanley
Sobreponderar
—
2026-10-07
Morgan Stanley
2026-10-07
Precio objetivo
—
Sobreponderar
JPMorgan
Sobreponderar
—
2026-09-28
JPMorgan
2026-09-28
Precio objetivo
—
Sobreponderar
Guggenheim
Comprar
—
2026-09-18
Guggenheim
2026-09-18
Precio objetivo
—
Comprar
Métricas de valoración
El PER previsto actual de Eli Lilly and Co (LLY) es 24.39, frente a su media de 5 años de 40.89.
Escenarios de precio de Alphio AI para LLY
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con LLY en cartera
Cronología de eventos
Noticias
9.510-13FoolEli Lilly's Q3 Earnings Preview Focuses on Key Drug Sales
8.510-13FoolEli Lilly Stock Split Prospects Analyzed
4.510-14PRnewswireMarket Volatility Intensifies as Tech Stocks Struggle
4.510-14CNBCUS Stocks Decline Due to Inflation Data
8.510-14stocktwitsViking Launches Phase 3 Trials for VK2735 Weight Loss Drug
Preguntas frecuentes sobre LLY, respondidas por Alphio AI
Eli Lilly and Company is a medicine company which discovers, develops, manufactures, and markets products in a single business segment called human pharmaceutical products. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. Its Cardiometabolic Health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients. The Company’s products are sold in approximately 90 countries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Eli Lilly is a good buy right now due to its current price of $1179.27, a strong year-to-date change of +9.16%, and a forward P/E ratio of 24.39, which suggests growth potential. The main risk is the high debt to equity ratio of 162.07%, indicating potential financial strain.
22 analysts cover LLY: 13 rate it Buy, 8 Hold and 1 Sell. The average price target is 1,192.
Comunidad
Más ↗
🚨 $VKTX just took a major step toward bringing its obesity pill to market! Viking Therapeutics has initiated two Phase 3 trials of oral VK2735, targeting patients with obesity both with and without Type 2 diabetes. 📊 Phase 2 results showed up to 12.2% mean weight loss in just 13 weeks, versus 1.3% with placebo. 🔥 The bigger picture? > Injectable VK2735 is already in Phase 3, with enrollment completed in both studies. > Maintenance data showed patients retained 85–90% of prior weight loss with less frequent injections. > Oral maintenance research and VK3019 add further potential to the pipeline. Competition from $LLY and $NVO is heating up, but Viking is expanding its options across oral, injectable and maintenance treatments.
Mostrar más
During market weakness, it's always good to watch which names are still holding up. Right now $LLY fits that description. It's breaking out to the upside and looks like it could drift up to its highs.
Mostrar más
Rotation into defensive sectors like healthcare this morning. Here's $LLY, which continues to set up constructively.
Mostrar más
$NVO $LLY Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro - Reuters
Mostrar más
VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 'Multi-Blockbusters' $VKTX $NVO $LLY $GPCR $ALT
Mostrar másEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.